Lord, Abbett & Co
CSTL icon

Lord, Abbett & Co’s Castle Biosciences CSTL Stock Holding History

Lord, Abbett & Co’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-205,036
Closed -$9.2M – 576
2022
Q1 		$9.2M Buy
205,036
+46,226
+29% +$1.91M 0.02% 470
2021
Q4 		$6.81M Sell
158,810
-1,550
-1% -$81K 0.02% 529
2021
Q3 		$10.7M Buy
160,360
+62,260
+63% +$4.38M 0.03% 522
2021
Q2 		$7.19M Sell
98,100
-95,349
-49% -$6.3M 0.02% 578
2021
Q1 		$13.2M Sell
193,449
-24,227
-11% -$1.82M 0.03% 479
2020
Q4 		$14.6M Buy
217,676
+35,608
+20% +$1.93M 0.04% 465
2020
Q3 		$9.37M Buy
182,068
+21,129
+13% +$940K 0.03% 483
2020
Q2 		$6.07M Buy
160,939
+23,870
+17% +$816K 0.02% 551
2020
Q1 		$4.09M Sell
137,069
-41,127
-23% -$1.24M 0.02% 560
2019
Q4 		$6.13M Buy
+178,196
New +$4.36M 0.02% 581

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.65B AUM 23.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Lord, Abbett & Co's CSTL Position: Q2 2022 in Review

Lord, Abbett & Co sold out of Castle Biosciences (CSTL) in Q2 2022, closing a stake of 205,036 shares — an estimated $9.2M sold.

Lord, Abbett & Co first reported a position in CSTL in Q4 2019 and held it in 10 quarters. The position peaked at $14.6M in Q4 2020. 146 funds tracked by Wall St. Rank hold CSTL as of Q2 2022.

  • Lord, Abbett & Co reported no remaining Castle Biosciences position as of Q2 2022 after selling out during the quarter.
  • Lord, Abbett & Co sold 205,036 Castle Biosciences shares in Q2 2022, an estimated $9.2M.
  • Lord, Abbett & Co first reported a position in Castle Biosciences in Q4 2019 and held it in 10 quarters.
  • Lord, Abbett & Co's Castle Biosciences position peaked at $14.6M in Q4 2020.
  • 146 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2022.

Based on Lord, Abbett & Co's 13F filing for Q2 2022, filed 12 Aug 2022.